Lead Product(s): Piroxicam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
The primary objective of the study was to determine the PK and relative bioavailability of piroxicam following oral administration of single 20 mg nanoformed piroxicam IR tablets and reference product Felden 20mg tablets (Pfizer) in healthy subjects in the fasted state.